Event in Progress:
Discover the latest content that has just been published on Research Tree
The management fully confirmed the FY guidance despite the fact that it was reached after nine months. In the call the management flagged some uncertainties which overhang the performance in the Q4. As destocking seems to be becoming the common denominator in the chemicals industry, we understand why companies are opting for caution.
Sales (+6.2%) and adjusted EBITDA (+4.4%) were a clear beat to consensus. The FY consensus currently stands at €2,093m very close to the company’s guidance.
Companies: Arkema (AKE:EPA)Arkema SA (AKE:PAR)
Arkema is now much more fun to cover after a long period of high cyclicality and poor results. For the moment all this is behind us and the management is currently basking in the results of all its hard work. Thing could change rapidly however.
Q2 was another consensus-beating quarter (sales: +22.9%; EBITDA: +16.0%), giving the management enough headroom to again raise its guidance after the most recent upgrade in Q1.
Companies: Arkema SA (0IB0:LON)Arkema SA (AKE:PAR)
Arkema is ‘sailing’ ahead of the cost curve. In our view, this was the main reason for the management to raise the bar. In the call, the management shed some light on the Q2, expecting strong growth at EBITDA level.
We are struggling a bit with the low consensus as the beat was substantial (+7.7% to sales, +42.6% to adjusted EBITDA and +52.2% to adjusted EPS). Other companies would have released preliminary figures.
The headline does not imply that Arkema is taking a nap, but another record race should not be expected and the step up is an inorganic one. The 2021 figures were a beat to consensus (sales: +4.2%; adjusted EBITDA: +6.0%).
Against the background of the war in Ukraine, we became less optimistic than management.
Arkema was in a position to implement (strong) price increases even in businesses where the company had a ‘tradition’ of suffering from higher raw material prices. We believe availability was also a strong argument. Interestingly, Adhesive Solutions did not benefit as strongly as the other divisions.
Q3 figures were above our cautious expectations and beat consensus expectations by +16.4% (top line) and +13.9% (EBITDA).
… to become a speciality chemicals company by 2024, by acquiring something pharma-like. Basically, Arkema plans to acquire the US-based adhesive platforms corralled together at Ashland’s Performance Adhesives business. The charm of the acquisition is that the acquired technologies will be globally rolled out, giving Arkema’s portfolio a broader stance. Management is quite optimistic it can generate substantial synergies including some positive tax effects, which should make the high valuation a
Arkema surfs the chemicals wave well, being carried along by the strong recovery. Supply availability is one side of the coin. On the other, stands cash collection and the company was good at this. Business-wise, the paved path seems to be a well-chosen one.
We appreciate the guidance increase, but do not understand that it is based on an unchanged scope after the closing the PMMA divestment.
Consensus was beaten by +5.7% (top line) and +21% (adjusted EBITDA).
The top line has already matched the Q1 19 level, but profitability could not fully catch up, despite the optimised business structure, which might be related to the strongly rising raw material prices. Additionally, management managed the organic momentum of the growth well as NWC outflow remained quite stable. Management has become more optimistic after the clear beat in its Q1 guidance.
Figures were slightly above our expectations and beat street estimates.
Arkema’s increasing footprint in speciality chemicals helped to protect profitability. Furthermore, management has taken the next steps towards the mid-term target, even in a crisis. By divesting PMMA, its has taken advantage of a special situation, allowing for a decent valuation.
Unfortunately, the company still fully consolidates the to-be-divested business showing up our estimates. Consensus was clearly beaten as it still included the PMMA business.
Like other chemicals companies, Arkema had to manoeuvre in challenging times, but the adhesives business was an anchor with its quite resilient business. The other divisions were in rough seas, as expected, giving a mixed picture from a variety of impacts. Intermediates was negatively affected by all factors. The newly-provided guidance looks like a strong commitment.
The Q3 figures were a notch stronger than expected, but matched well with the street’s expectations.
Companies: Arkema SA
Like other chemicals, Arkema could not escape from the developments in the customer markets. Nevertheless, the speciality side of the company did quite well despite some meaningful declines in volumes, whereas Intermediates was hit by lower volumes and lower prices. All divisions saw a strong drop in profitability. The divestment proceeds of Functional Polyolefines were a tonic and helped profitability to beat our expectations. Consensus was also beaten.
Arkema’s business model is still a chemicals one, even though the specialities’ share has increased in the recent past. Interestingly, management’s strategy to focus on adhesives seems to be paying off. In addition to the spreading virus, the country, where Arkema has its headquarters, also had an adverse impact on profitability. Q1 came in a notch weaker than we expected. Consensus was perfectly met.
Arkema reported a better than expected set of figures (consensus was perfectly met on the profitability level). The portfolio changes in recent years have made the company’s financial mechanics more resilient to economic downturns. Despite all current uncertainties, management seems to be quite optimistic for 2020 – at first sight. But it has excluded any virus-triggered effects, which are estimated to be around €20m by the end of February.
The good point is that the EBITDA margin has not faded away as Arkema’s top-line was driven by an acquisition and FX tailwinds. However, lower raw material prices put some pressure on it. Volumes developed positively in most divisions.
Reported figures beat our expectations, but were below consensus. For Q4, we remain cautious.
At Group level, given the tough environment, Arkema’s results proved fairly resilient. After the company’s ‘overhaul’ in recent years and the increase in the proportion of specialties’ sales (to 71%), no one would have expected Coatings Solutions to report higher profitability. Despite confirming FY guidance, management indicated some weakness in H2. The figures did not fully meet our expectations (profitability undershoot), but consensus was beaten.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Arkema SA.
We currently have 31 research reports from 2
Companies: Invinity Energy Systems PLC
On 10 January last year, we set out our ten top stock picks for 2022, in what turned out to be a very poor twelve months for global equities, due to war, accelerating inflation, political instability and recession fears. Between 7 January 2022 and 31 December 2022, the AIM All-Share Index declined 30.0%, whilst the average performance of our ten top picks was -24.7%, a modest relative outperformance. In this note we discuss the performance of our 2022 top picks, equities trends in 2022, and our
Companies: GHH SCE BGO TPT ZOO ASTO INCH DWF EQLS NXR
Companies: EQTEC PLC
• ITM has released a trading update, reporting on progress of the detailed review being carried out under its new CEO. This includes a profit warning, with FY 2023 results now expected to exhibit lower revenue and a higher EBITDA loss than previous guidance (existing guidance was to be at the lower end of the range on output of 48-65MW and £23-28m revenue, and was also for EBITDA loss of £45-50m), with the difference described as “material”. This has been driven by several factors: losses on cus
Companies: ITM Power PLC
Performance - 2022 ended with another difficult month for property companies as the sector continues to get to grips with the impact of higher interest rates. There were several funds that performed well during December, however, with secondary shopping centre landlord Capital & Regional top of the pile. For a second month on the trot Home REIT saw its share price tank after it came under attack from a short seller in November.
Valuation moves - It was a mixed bag for valuations, with six-month
Companies: GWW GWW TOWN API RLE LMP CAPC WHR CSH ASLI PCA EBOX RGLZ ESP PHP SHED SRE MLI RGL CRC CBA DELMUR
Companies: ITM IOG KOD AVCT
Companies: Yu Group PLC
Strix have issued a full year trading update indicating profit after tax will be c. £23.0m, in line with updated guidance provided in the 30 November 2022 trading update following completion of the Billi acquisition. Year-end net debt came in at £87.0m, slightly ahead of Zeus forecasts, leaving the company well placed to bring net debt / EBITDA materially below 2.0x during FY23. Profitability being in line provides confidence that the Zeus FY22 revenue forecast of £110.0m will be achieved, imply
Companies: Strix Group PLC
Capital Limited (LSE: CAPD) this morning provided its Q4 & FY2022 trading update. The Company has continued to perform strongly in 2022 with Q4 revenue 8.2% higher QoQ and 18.9% higher YoY. The full year of revenue has once again exceeded the revised guidance (albeit marginally) and our estimates.
Companies: Capital Limited
We see Invinity’s update as reassuring and the new commercial sale adds to this especially as it is a second sale through an existing partner. Year-end cash of £5.1m and £7.5m of further potential convertible funding aligns with a strong order backlog and pipeline growth to give comfort for FY 23 and beyond in our view.
Powerhouse is making progress in Poland. This is potentially a major opportunity for Powerhouse, and establishing a project here using its technology could open a potentially strong market in our view.
Companies: Powerhouse Energy Group PLC
Companies: eEnergy Group PLC
Companies: Kier Group plc
17 January 2023
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: RNO WINE CNS HVO HVO RFX KIBO